Statistics for Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia
Total visits
| views | |
|---|---|
| Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia | 67 |
Total visits per month
| views | |
|---|---|
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
File Visits
| views | |
|---|---|
| 223_2020_Article_797.pdf | 28 |
| java.util.UUID:b6fe75e9-ae48-47c7-a934-54af184ccc8e | 27 |
| java.util.UUID:0c476634-0d9b-478b-b766-7fa5654aded6 | 7 |
| java.util.UUID:0c55a080-797a-4e85-b126-761fee4ceba8 | 5 |
Top country views
| views | |
|---|---|
| United States | 55 |
| France | 1 |
| South Korea | 1 |
| Malaysia | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 37 |
| Fairfield | 9 |
| Ann Arbor | 1 |
| Baltimore | 1 |
| Bartlesville | 1 |
| Bloomington | 1 |
| Cambridge | 1 |
| Houston | 1 |
| Nanterre | 1 |
| Seremban | 1 |